BIOMAT Database Logo BIOMAT Database Logo

Engineering the C-region of human insulin-like growth factor-1: implications for receptor binding. 1996

R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
Department of Crystallography, Birkbeck College, London.

Recombinant wild-type human IGF-1 and a C-region mutant in which residues 28-37 have been replaced by a 4-glycine bridge (4-Gly IGF-1) were secreted and purified from yeast. An IGF-1 analogue in which residues 29-41 of the C-region have been deleted (mini IGF-1) was created by site-directed mutagenesis and also expressed. All three proteins adopted the insulin-fold as determined by circular dichroism. The significantly raised expression levels of mini IGF-1 allowed the recording of two-dimensional NMR spectra. The affinity of 4-Gly IGF-1 for the IGF-1 receptor was approximately 100-fold lower than that of wild-type IGF-1 and the affinity for the insulin receptor was approximately 10-fold lower. Mini IGF-1 showed no affinity for either receptor. Not only does the C-region of IGF-1 contribute directly to the free energy of binding to the IGF-1 receptor, but also the absence of flexibility in this region eliminates binding altogether. As postulated for the binding of insulin to its own receptor, it is proposed that binding of IGF-1 to the IGF-1 receptor also involves a conformational change in which the C-terminal B-region residues detach from the body of the molecule to expose the underlying A-region residues.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D008297 Male Males
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D002942 Circular Dichroism A change from planar to elliptic polarization when an initially plane-polarized light wave traverses an optically active medium. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Circular Dichroism, Vibrational,Dichroism, Circular,Vibrational Circular Dichroism
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning

Related Publications

R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor.
July 1989, The Journal of biological chemistry,
R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
Insulin-like growth factor binding protein-2: contributions of the C-terminal domain to insulin-like growth factor-1 binding.
March 2006, Molecular pharmacology,
R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
Insulin-like growth factor-1 and insulin-like growth factor binding protein-1 in early human pregnancy.
February 1992, Early human development,
R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
Quantitative analysis of insulin-like growth factor 2 receptor and insulin-like growth factor binding proteins to identify control mechanisms for insulin-like growth factor 1 receptor phosphorylation.
February 2016, BMC systems biology,
R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6.
May 1993, The Journal of biological chemistry,
R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
Engineering insulin-like growth factor-1 for local delivery.
June 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology,
R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
Direct integrin binding to insulin-like growth factor-2 through the C-domain is required for insulin-like growth factor receptor type 1 (IGF1R) signaling.
January 2017, PloS one,
R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor.
May 1988, Biochemistry,
R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
Insulin-like growth factor-1 mRNA isoforms and insulin-like growth factor-1 receptor mRNA expression in chronic hepatitis C.
April 2015, World journal of gastroenterology,
R Gill, and B Wallach, and C Verma, and B Ursø, and E De Wolf, and J Grötzinger, and J Murray-Rust, and J Pitts, and A Wollmer, and P De Meyts, and S Wood
Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy.
September 2009, Current cancer drug targets,
Copied contents to your clipboard!